Table 1 Demographics, on-arrival presentation, and treatment response by group
| Variable |
Total (n = 30) |
Lorazepam (n = 15) |
Clonazepam (n = 15) |
P
(MWU test) |
|---|---|---|---|---|
| Median [IQR] (range) | ||||
| Age (months) |
15 [10, 36] (6, 144) |
15 [10, 37] (6, 144) |
17 [11, 33] (6, 84) | 0.637 |
| Weight (kg) |
11 [10,14] (6.5, 40) |
11.5 [9.5, 15] (8, 40) |
10.7 [10,, 13.7] (6.5, 25) | 0.697 |
| Time elapsed between exposure and presentation (h) |
3 [5,6] (1, 72) |
5 [4,9] (2, 72) |
3 [5,6] (1, 14) | 0.377 |
| Time elapsed between exposure and the development of symptoms (h) |
1 [1,2] (0.5, 24) |
1 [1,, 2.2] (0.5, 24) |
1 [1,2] (0.5, 2) | 0.275 |
| Presentation on arrival | ||||
| Temperature (C) |
37 [36.5, 37] (36, 37.7) |
36.9 [36.5, 37] (36, 37.3) |
37 [36.7, 37.1] (36.5, 37.5) | 0.142 |
| Systolic BP (mmHg) |
90 [90, 100] (80, 110) |
92 [90, 100] (80, 110) |
90 [90, 100] (80, 110) | 0.400 |
| Diastolic BP (mmHg) |
50 [50, 60] (40, 80) |
60 [50, 70] (50, 80) |
50 [50, 60] (40, 70) | 0.160 |
| Heart rate (per minute) |
127 [110, 140] (90, 160) |
130 [110, 150] (92, 160) |
120 [102, 140] (90, 150) | 0.498 |
| Respiratory rate (per minute) |
30 [27, 35] (16, 60) |
31[26, 35] (22, 60) |
30 [28, 34] (16, 60) | 0.667 |
| Creatine phosphokinase (U/L) |
218 [148, 360] (88, 1584) |
225 [148, 461] (117, 698) |
211[126, 324] (88, 1584) | 0.697 |
| Treatment response | ||||
| Duration of symptoms (h) |
4 [3,5] (2, 20) |
3 [2,4] (2, 13) |
5 [3,7] (2, 20) | 0.166 |
| Hospitalization period (h) |
24 [24, 48] (24, 72) |
24 [24, 48] (24, 48) |
24 [24, 42] (24, 72) | 0.525 |